Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 10:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 27,950 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Efficacy Clear all
Terminated Not applicable Interventional Accepts healthy volunteers

Effectiveness of Autologous Platelet Rich Plasma in the Treatment of Chronic Non-Healing Wounds

NCT02307448
View directory record Official record
Conditions
Foot Ulcer Chronic, Skin Ulcer Venous Stasis Chronic, Pressure Ulcer
Interventions
Platelet Rich Plasma, Standard of Care
Procedure
Lead sponsor
ACR Biologics, LLC
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2022
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 31, 2023 · Synced Sep 8, 2026, 10:29 AM EDT
Not listed Not applicable Interventional

Access Safety and Efficacy Post Endovascular Intervention

NCT01773148
View directory record Official record
Conditions
Cardiovascular Disease.
Interventions
Arstasis Access System (AXERA)
Device
Lead sponsor
Arstasis, Inc.
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
17
States / cities
Huntsville, Alabama • Little Rock, Arkansas • La Jolla, California + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2015 · Synced Sep 8, 2026, 10:29 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors

NCT02440685
View directory record Official record
Conditions
Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell, Lymphoma, Follicular, Cancer, Neoplasm, Tumor, Lymphoma, Malignant, Lymphoma, B-cell, Lymphoma, Non-Hodgkin, B-Cell Chronic Lymphocytic Leukemia, B-Cell Leukemia, Chronic, B-Lymphocytic Leukemia, Chronic, Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Chronic, Leukemia, Lymphocytic, Chronic, B Cell, Myelofibrosis, Chronic Idiopathic Myelofibrosis, Idiopathic Myelofibrosis, Lymphoma, T Cell, Peripheral, Peripheral T-Cell Lymphoma, T-Cell Lymphoma, Peripheral
Interventions
ASN002 Dose Escalation, ASN002 RD
Drug
Lead sponsor
Asana BioSciences
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
12
States / cities
Tempe, Arizona • San Francisco, California • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2023 · Synced Sep 8, 2026, 10:29 AM EDT
Completed Phase 1Phase 2 Interventional Results available

An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer

NCT01658878
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Nivolumab, Sorafenib, Ipilimumab, Cabozantinib
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
657 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
10
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Pensacola, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Sep 8, 2026, 10:29 AM EDT
Completed Phase 3 Interventional

A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Pachyonychia Congenita

NCT05180708
View directory record Official record
Conditions
Pachyonychia Congenita
Interventions
QTORIN 3.9% rapamycin anhydrous gel, Vehicle
Drug
Lead sponsor
Palvella Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
7
States / cities
Palo Alto, California • New Haven, Connecticut • Orange Park, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2024 · Synced Sep 8, 2026, 10:29 AM EDT
Withdrawn Phase 3 Interventional

Efficacy of Coenzyme Q10 Supplementation on Multi-Organ Dysfunction in Severely Burned Patients

NCT03968640
View directory record Official record
Conditions
Multiple Organ Failure
Interventions
CoQ10, Placebo
Dietary Supplement
Lead sponsor
American Burn Association
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 19, 2023 · Synced Sep 8, 2026, 10:29 AM EDT
Completed Phase 4 Interventional Results available

MirvasO Soolantra Association In the Treatment of Moderate to Severe rosaCea.

NCT02616250
View directory record Official record
Conditions
Rosacea
Interventions
Brimonidine 0.33% gel (Br), CD07805/47 (Br) placebo gel, Ivermectin 1% cream (IVM), CD5024 (IVM) placebo cream
Drug · Other
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
7
States / cities
Fort Smith, Arkansas • Rogers, Arkansas • Sacramento, California + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Sep 8, 2026, 10:29 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of Angiotech Central Venous Catheter to Prevent Bacterial Catheter Colonization

NCT00288418
View directory record Official record
Conditions
Bacterial Infections
Interventions
Central Venous Catheter
Device
Lead sponsor
Angiotech Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
960 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
21
States / cities
Birmingham, Alabama • Orange, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2013 · Synced Sep 8, 2026, 10:29 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Noise in the OR: A Quality Improvement Program

NCT04722497
View directory record Official record
Conditions
Noise; Adverse Effect
Interventions
Sound Education
Other
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
1,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 24, 2021 · Synced Sep 8, 2026, 10:29 AM EDT
Not listed Phase 1 Interventional

A Phase 1b Study to Evaluate APL-1401 in Patients With Moderately to Severely Active Ulcerative Colitis

NCT05743010
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
APL-1401, Placebo
Drug
Lead sponsor
Jiangsu Yahong Meditech Co., Ltd aka Asieris
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
4
States / cities
Corona, California • Tampa, Florida • Marrero, Louisiana + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2023 · Synced Sep 8, 2026, 10:29 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Efficacy and Safety of a Nanofat-seeded Biological Scaffold in Healing Lower Limb Surgical Defects

NCT03548610
View directory record Official record
Conditions
Wound of Skin, Non-melanoma Skin Cancer, Skin Graft Complications, Wound of Lower Leg, Wound of Knee
Interventions
Nanofat-seeded biological scaffold on surgical defect
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 10, 2020 · Synced Sep 8, 2026, 10:29 AM EDT
Completed No phase listed Observational

Long-Term Safety and Effectiveness of MDMA-Assisted Therapy for PTSD

NCT05066282
View directory record Official record
Conditions
PTSD
Interventions
Not listed
Lead sponsor
Resilient Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 29, 2024 · Synced Sep 8, 2026, 10:29 AM EDT
Suspended Phase 2 Interventional

TOP 2301: Neoadjuvant Chemo for NSCLC

NCT06385262
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Alirocumab, Cemiplimab, Chemotherapy
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 8, 2026, 10:29 AM EDT
Terminated Phase 3 Interventional Results available

Study of Safety, Efficacy and Tolerability of Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis

NCT04181762
View directory record Official record
Conditions
Lupus Nephritis
Interventions
secukinumab, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
8
States / cities
Birmingham, Alabama • Fontana, California • Los Angeles, California + 5 more
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Sep 8, 2026, 10:29 AM EDT
Completed Phase 3 Interventional

TMC125-C206: A Phase III Study to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen, Including TMC114/Ritonavir and an Investigator-selected Optimized Background, in HIV-1 Infected Patients With Limited to no Treatment Options.

NCT00254046
View directory record Official record
Conditions
HIV
Interventions
TMC125, Placebo
Drug
Lead sponsor
Tibotec Pharmaceuticals, Ireland
Industry
Eligibility
18 Years and older
Enrollment
616 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
32
States / cities
Little Rock, Arkansas • Beverly Hills, California • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2014 · Synced Sep 8, 2026, 10:29 AM EDT
Completed Not applicable Interventional Results available

Vitamin D Absorption in HIV Infected Young Adults Being Treated With Tenofovir Containing cART

NCT01751646
View directory record Official record
Conditions
HIV Infection
Interventions
Vitamin D3 50,000 IU, Vitamin D3 placebo
Dietary Supplement
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
16 Years to 24 Years
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
16
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Fort Lauderdale, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Sep 8, 2026, 10:29 AM EDT
Completed Not applicable Interventional Results available

Low Intensity Shock Wave Therapy in the Management of Erectile Dysfunction

NCT04136288
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
MoreNova
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years to 55 Years · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 11, 2024 · Synced Sep 8, 2026, 10:29 AM EDT
Completed Phase 2 Interventional Results available

Efficacy, Tolerability, and Pharmacokinetics of Multiple Doses of Oral TAK-831 in Adults With Friedreich Ataxia

NCT03214588
View directory record Official record
Conditions
Friedreich Ataxia
Interventions
TAK-831, TAK-831 Placebo
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
6
States / cities
Los Angeles, California • Gainesville, Florida • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2021 · Synced Sep 8, 2026, 10:29 AM EDT
Not listed Phase 2 Interventional

MRG-001 as an Immunoregulatory and Regenerative Therapy for COVID-19 Patients

NCT04646603
View directory record Official record
Conditions
COVID-19, ARDS, Human, Stem Cells, Regeneration
Interventions
MRG-001, Placebo
Drug
Lead sponsor
MedRegen LLC
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 14, 2022 · Synced Sep 8, 2026, 10:29 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Sacituzumab Govitecan in Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Second Generation AR-Directed Therapy

NCT03725761
View directory record Official record
Conditions
Prostate Cancer
Interventions
Sacituzumab Govitecan
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Male only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
3
States / cities
New York, New York • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 8, 2026, 10:29 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Efficacy and Safety of 5-day Dosing of ON 01910.Na in Intermediate-1,-2, or High Risk Myelodysplastic Syndrome (MDS)

NCT00867061
View directory record Official record
Conditions
Myelodysplastic Syndrome
Interventions
ON 01910.Na Concentrate
Drug
Lead sponsor
Traws Pharma, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 22, 2017 · Synced Sep 8, 2026, 10:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Improving HIV Screening With Nurse-Based Rapid Testing/Streamlined Counseling

NCT00119548
View directory record Official record
Conditions
Health Care Quality, Access, and Evaluation, Delivery of Health Care, Immune System Diseases, HIV Infections
Interventions
Rates of HIV testing and receipt of results, Sexual risk reduction; HIV knowledge improvement
Other
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 65 Years
Enrollment
251 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
West Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 6, 2015 · Synced Sep 8, 2026, 10:29 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study of the Effects of 6R-BH4 in Subjects With Sickle Cell Disease

NCT00445978
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Sapropterin Dihydrochloride
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
15 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
12
States / cities
Washington D.C., District of Columbia • Augusta, Georgia • Savannah, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2021 · Synced Sep 8, 2026, 10:29 AM EDT
Active, not recruiting Not applicable Interventional

The Heart Health After Cardiac Treatment Study

NCT07158515
View directory record Official record
Conditions
Cardiac Rehabilitation
Interventions
Tailored cardiac rehabilitation, Referral to an external cardiac rehabilitation program
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 8, 2026, 10:29 AM EDT